NASDAQ:VCNX - Vaccinex Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 171.32 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.58
▼ -0.05 (-1.90%)

This chart shows the closing price for VCNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vaccinex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VCNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VCNX

Analyst Price Target is $7.00
▲ +171.32% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vaccinex in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 171.32% upside from the last price of $2.58.

This chart shows the closing price for VCNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Vaccinex.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/25/2020OppenheimerLower Price TargetOutperform$22.00 ➝ $7.00Medium
9/22/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
8/17/2020OppenheimerReiterated RatingBuy$22.00Low
5/18/2020OppenheimerReiterated RatingBuy$22.00Low
4/27/2020OppenheimerReiterated RatingBuy$22.00High
1/16/2019OppenheimerSet Price TargetBuy$22.00High
11/13/2018OppenheimerSet Price TargetBuy$22.00Medium
9/4/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$22.00Medium
9/4/2018OppenheimerInitiated CoverageBuy$22.00High
9/4/2018BTIG ResearchInitiated CoverageBuyHigh
(Data available from 6/21/2016 forward)
Vaccinex logo
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Read More

Today's Range

Now: $2.58
Low: $2.55
High: $2.63

50 Day Range

MA: $2.43
Low: $2.01
High: $3.00

52 Week Range

Now: $2.58
Low: $1.63
High: $9.56

Volume

5,214 shs

Average Volume

3,264,229 shs

Market Capitalization

$73.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaccinex?

The following sell-side analysts have issued research reports on Vaccinex in the last year: BTIG Research, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for VCNX.

What is the current price target for Vaccinex?

1 Wall Street analysts have set twelve-month price targets for Vaccinex in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 171.3%. Oppenheimer Holdings Inc. has the highest price target set, predicting VCNX will reach $7.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $7.00 for Vaccinex in the next year.
View the latest price targets for VCNX.

What is the current consensus analyst rating for Vaccinex?

Vaccinex currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VCNX will outperform the market and that investors should add to their positions of Vaccinex.
View the latest ratings for VCNX.

What other companies compete with Vaccinex?

How do I contact Vaccinex's investor relations team?

Vaccinex's physical mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company's listed phone number is 585-271-2700 and its investor relations email address is [email protected] The official website for Vaccinex is www.vaccinex.com.